カテゴリー： QYResearch, 世界

多嚢胞性卵巣症候群の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書（QY21APR4692）
◆英語タイトル：Global Polycystic Ovary Syndrome Market Size, Status and Forecast 2021-2027
◆商品コード：QY21APR4692
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2021年4月
◆ページ数：127
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥499,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥748,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
本調査資料では、多嚢胞性卵巣症候群の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（利尿剤、インスリン増感剤、抗アンドロゲン剤、抗うつ剤、オルニチンデカルボキシラ）、用途別市場規模（病院薬局、ドラッグストア、小売薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・多嚢胞性卵巣症候群の市場動向
・企業の競争状況、市場シェア
・多嚢胞性卵巣症候群の種類別市場規模（利尿剤、インスリン増感剤、抗アンドロゲン剤、抗うつ剤、オルニチンデカルボキシラ）
・多嚢胞性卵巣症候群の用途別市場規模（病院薬局、ドラッグストア、小売薬局）
・多嚢胞性卵巣症候群の北米市場規模2016-2027（アメリカ、カナダ）
・多嚢胞性卵巣症候群の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・多嚢胞性卵巣症候群のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・多嚢胞性卵巣症候群の中南米市場規模2016-2027（メキシコ、ブラジル）
・多嚢胞性卵巣症候群の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Abbott Laboratories、Addex therapeutics、Himalaya、Astellas Pharma、AstraZeneca、Ava Science、Bayer、Bristol-Myers Squibb、Theralogix、Ferring Pharmaceuticals、Teva Pharmaceutical、GSK、Sneha Natura、Jarrow Formulas、Merck、Millendo Therapeutics、MyOva、Novartis、Ogeda、PCOS Diva、Pharmasure、Salveo Lifecare）
・結論
【レポートの概要】

Market Analysis and Insights: Global Polycystic Ovary Syndrome Market
The global Polycystic Ovary Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Polycystic Ovary Syndrome market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Polycystic Ovary Syndrome market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Polycystic Ovary Syndrome market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Polycystic Ovary Syndrome market.

Global Polycystic Ovary Syndrome Scope and Market Size
Polycystic Ovary Syndrome market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Polycystic Ovary Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Diuretics
Insulin sensitizing agents
Antiandrogens
Anti-depressants
Ornithine decarboxylase inhibitors

Segment by Application
Hospital pharmacies
Drug stores
Retail pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Addex therapeutics
Himalaya
Astellas Pharma
AstraZeneca
Ava Science
Bayer
Bristol-Myers Squibb
Theralogix
Astellas Pharma
AstraZeneca
GSK
Sneha Natura
Jarrow Formulas
Merck
Millendo Therapeutics
MyOva
Novartis
Ogeda
PCOS Diva

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Polycystic Ovary Syndrome Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Diuretics
1.2.3 Insulin sensitizing agents
1.2.4 Antiandrogens
1.2.5 Anti-depressants
1.2.6 Ornithine decarboxylase inhibitors
1.3 Market by Application
1.3.1 Global Polycystic Ovary Syndrome Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital pharmacies
1.3.3 Drug stores
1.3.4 Retail pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Polycystic Ovary Syndrome Market Perspective (2016-2027)
2.2 Polycystic Ovary Syndrome Growth Trends by Regions
2.2.1 Polycystic Ovary Syndrome Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Polycystic Ovary Syndrome Historic Market Share by Regions (2016-2021)
2.2.3 Polycystic Ovary Syndrome Forecasted Market Size by Regions (2022-2027)
2.3 Polycystic Ovary Syndrome Industry Dynamic
2.3.1 Polycystic Ovary Syndrome Market Trends
2.3.2 Polycystic Ovary Syndrome Market Drivers
2.3.3 Polycystic Ovary Syndrome Market Challenges
2.3.4 Polycystic Ovary Syndrome Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Polycystic Ovary Syndrome Players by Revenue
3.1.1 Global Top Polycystic Ovary Syndrome Players by Revenue (2016-2021)
3.1.2 Global Polycystic Ovary Syndrome Revenue Market Share by Players (2016-2021)
3.2 Global Polycystic Ovary Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Polycystic Ovary Syndrome Revenue
3.4 Global Polycystic Ovary Syndrome Market Concentration Ratio
3.4.1 Global Polycystic Ovary Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Polycystic Ovary Syndrome Revenue in 2020
3.5 Polycystic Ovary Syndrome Key Players Head office and Area Served
3.6 Key Players Polycystic Ovary Syndrome Product Solution and Service
3.7 Date of Enter into Polycystic Ovary Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Polycystic Ovary Syndrome Breakdown Data by Type
4.1 Global Polycystic Ovary Syndrome Historic Market Size by Type (2016-2021)
4.2 Global Polycystic Ovary Syndrome Forecasted Market Size by Type (2022-2027)

5 Polycystic Ovary Syndrome Breakdown Data by Application
5.1 Global Polycystic Ovary Syndrome Historic Market Size by Application (2016-2021)
5.2 Global Polycystic Ovary Syndrome Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Polycystic Ovary Syndrome Market Size (2016-2027)
6.2 North America Polycystic Ovary Syndrome Market Size by Type
6.2.1 North America Polycystic Ovary Syndrome Market Size by Type (2016-2021)
6.2.2 North America Polycystic Ovary Syndrome Market Size by Type (2022-2027)
6.2.3 North America Polycystic Ovary Syndrome Market Size by Type (2016-2027)
6.3 North America Polycystic Ovary Syndrome Market Size by Application
6.3.1 North America Polycystic Ovary Syndrome Market Size by Application (2016-2021)
6.3.2 North America Polycystic Ovary Syndrome Market Size by Application (2022-2027)
6.3.3 North America Polycystic Ovary Syndrome Market Size by Application (2016-2027)
6.4 North America Polycystic Ovary Syndrome Market Size by Country
6.4.1 North America Polycystic Ovary Syndrome Market Size by Country (2016-2021)
6.4.2 North America Polycystic Ovary Syndrome Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Polycystic Ovary Syndrome Market Size (2016-2027)
7.2 Europe Polycystic Ovary Syndrome Market Size by Type
7.2.1 Europe Polycystic Ovary Syndrome Market Size by Type (2016-2021)
7.2.2 Europe Polycystic Ovary Syndrome Market Size by Type (2022-2027)
7.2.3 Europe Polycystic Ovary Syndrome Market Size by Type (2016-2027)
7.3 Europe Polycystic Ovary Syndrome Market Size by Application
7.3.1 Europe Polycystic Ovary Syndrome Market Size by Application (2016-2021)
7.3.2 Europe Polycystic Ovary Syndrome Market Size by Application (2022-2027)
7.3.3 Europe Polycystic Ovary Syndrome Market Size by Application (2016-2027)
7.4 Europe Polycystic Ovary Syndrome Market Size by Country
7.4.1 Europe Polycystic Ovary Syndrome Market Size by Country (2016-2021)
7.4.2 Europe Polycystic Ovary Syndrome Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Polycystic Ovary Syndrome Market Size (2016-2027)
8.2 Asia-Pacific Polycystic Ovary Syndrome Market Size by Type
8.2.1 Asia-Pacific Polycystic Ovary Syndrome Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Polycystic Ovary Syndrome Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Polycystic Ovary Syndrome Market Size by Type (2016-2027)
8.3 Asia-Pacific Polycystic Ovary Syndrome Market Size by Application
8.3.1 Asia-Pacific Polycystic Ovary Syndrome Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Polycystic Ovary Syndrome Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Polycystic Ovary Syndrome Market Size by Application (2016-2027)
8.4 Asia-Pacific Polycystic Ovary Syndrome Market Size by Region
8.4.1 Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Polycystic Ovary Syndrome Market Size (2016-2027)
9.2 Latin America Polycystic Ovary Syndrome Market Size by Type
9.2.1 Latin America Polycystic Ovary Syndrome Market Size by Type (2016-2021)
9.2.2 Latin America Polycystic Ovary Syndrome Market Size by Type (2022-2027)
9.2.3 Latin America Polycystic Ovary Syndrome Market Size by Type (2016-2027)
9.3 Latin America Polycystic Ovary Syndrome Market Size by Application
9.3.1 Latin America Polycystic Ovary Syndrome Market Size by Application (2016-2021)
9.3.2 Latin America Polycystic Ovary Syndrome Market Size by Application (2022-2027)
9.3.3 Latin America Polycystic Ovary Syndrome Market Size by Application (2016-2027)
9.4 Latin America Polycystic Ovary Syndrome Market Size by Country
9.4.1 Latin America Polycystic Ovary Syndrome Market Size by Country (2016-2021)
9.4.2 Latin America Polycystic Ovary Syndrome Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Polycystic Ovary Syndrome Market Size (2016-2027)
10.2 Middle East & Africa Polycystic Ovary Syndrome Market Size by Type
10.2.1 Middle East & Africa Polycystic Ovary Syndrome Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Polycystic Ovary Syndrome Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Polycystic Ovary Syndrome Market Size by Type (2016-2027)
10.3 Middle East & Africa Polycystic Ovary Syndrome Market Size by Application
10.3.1 Middle East & Africa Polycystic Ovary Syndrome Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Polycystic Ovary Syndrome Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Polycystic Ovary Syndrome Market Size by Application (2016-2027)
10.4 Middle East & Africa Polycystic Ovary Syndrome Market Size by Country
10.4.1 Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Polycystic Ovary Syndrome Introduction
11.1.4 Abbott Laboratories Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.1.5 Abbott Laboratories Recent Development
11.2 Addex therapeutics
11.2.1 Addex therapeutics Company Details
11.2.2 Addex therapeutics Business Overview
11.2.3 Addex therapeutics Polycystic Ovary Syndrome Introduction
11.2.4 Addex therapeutics Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.2.5 Addex therapeutics Recent Development
11.3 Himalaya
11.3.1 Himalaya Company Details
11.3.2 Himalaya Business Overview
11.3.3 Himalaya Polycystic Ovary Syndrome Introduction
11.3.4 Himalaya Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.3.5 Himalaya Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Details
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Polycystic Ovary Syndrome Introduction
11.4.4 Astellas Pharma Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.4.5 Astellas Pharma Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Polycystic Ovary Syndrome Introduction
11.5.4 AstraZeneca Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.5.5 AstraZeneca Recent Development
11.6 Ava Science
11.6.1 Ava Science Company Details
11.6.2 Ava Science Business Overview
11.6.3 Ava Science Polycystic Ovary Syndrome Introduction
11.6.4 Ava Science Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.6.5 Ava Science Recent Development
11.7 Bayer
11.7.1 Bayer Company Details
11.7.2 Bayer Business Overview
11.7.3 Bayer Polycystic Ovary Syndrome Introduction
11.7.4 Bayer Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.7.5 Bayer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Polycystic Ovary Syndrome Introduction
11.8.4 Bristol-Myers Squibb Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Theralogix
11.9.1 Theralogix Company Details
11.9.2 Theralogix Business Overview
11.9.3 Theralogix Polycystic Ovary Syndrome Introduction
11.9.4 Theralogix Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.9.5 Theralogix Recent Development
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Company Details
11.10.2 Ferring Pharmaceuticals Business Overview
11.10.3 Ferring Pharmaceuticals Polycystic Ovary Syndrome Introduction
11.10.4 Ferring Pharmaceuticals Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.10.5 Ferring Pharmaceuticals Recent Development
11.11 Teva Pharmaceutical
11.11.1 Teva Pharmaceutical Company Details
11.11.2 Teva Pharmaceutical Business Overview
11.11.3 Teva Pharmaceutical Polycystic Ovary Syndrome Introduction
11.11.4 Teva Pharmaceutical Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.11.5 Teva Pharmaceutical Recent Development
11.12 GSK
11.12.1 GSK Company Details
11.12.2 GSK Business Overview
11.12.3 GSK Polycystic Ovary Syndrome Introduction
11.12.4 GSK Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.12.5 GSK Recent Development
11.13 Sneha Natura
11.13.1 Sneha Natura Company Details
11.13.2 Sneha Natura Business Overview
11.13.3 Sneha Natura Polycystic Ovary Syndrome Introduction
11.13.4 Sneha Natura Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.13.5 Sneha Natura Recent Development
11.14 Jarrow Formulas
11.14.1 Jarrow Formulas Company Details
11.14.2 Jarrow Formulas Business Overview
11.14.3 Jarrow Formulas Polycystic Ovary Syndrome Introduction
11.14.4 Jarrow Formulas Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.14.5 Jarrow Formulas Recent Development
11.15 Merck
11.15.1 Merck Company Details
11.15.2 Merck Business Overview
11.15.3 Merck Polycystic Ovary Syndrome Introduction
11.15.4 Merck Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.15.5 Merck Recent Development
11.16 Millendo Therapeutics
11.16.1 Millendo Therapeutics Company Details
11.16.2 Millendo Therapeutics Business Overview
11.16.3 Millendo Therapeutics Polycystic Ovary Syndrome Introduction
11.16.4 Millendo Therapeutics Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.16.5 Millendo Therapeutics Recent Development
11.17 MyOva
11.17.1 MyOva Company Details
11.17.2 MyOva Business Overview
11.17.3 MyOva Polycystic Ovary Syndrome Introduction
11.17.4 MyOva Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.17.5 MyOva Recent Development
11.18 Novartis
11.18.1 Novartis Company Details
11.18.2 Novartis Business Overview
11.18.3 Novartis Polycystic Ovary Syndrome Introduction
11.18.4 Novartis Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.18.5 Novartis Recent Development
11.18 Ogeda
.1 Ogeda Company Details
.2 Ogeda Business Overview
.3 Ogeda Polycystic Ovary Syndrome Introduction
.4 Ogeda Revenue in Polycystic Ovary Syndrome Business (2016-2021)
.5 Ogeda Recent Development
11.20 PCOS Diva
11.20.1 PCOS Diva Company Details
11.20.2 PCOS Diva Business Overview
11.20.3 PCOS Diva Polycystic Ovary Syndrome Introduction
11.20.4 PCOS Diva Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.20.5 PCOS Diva Recent Development
11.21 Pharmasure
11.21.1 Pharmasure Company Details
11.21.2 Pharmasure Business Overview
11.21.3 Pharmasure Polycystic Ovary Syndrome Introduction
11.21.4 Pharmasure Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.21.5 Pharmasure Recent Development
11.22 Salveo Lifecare
11.22.1 Salveo Lifecare Company Details
11.22.2 Salveo Lifecare Business Overview
11.22.3 Salveo Lifecare Polycystic Ovary Syndrome Introduction
11.22.4 Salveo Lifecare Revenue in Polycystic Ovary Syndrome Business (2016-2021)
11.22.5 Salveo Lifecare Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 多嚢胞性卵巣症候群の世界市場規模・現状・予測2021年-2027年(Global Polycystic Ovary Syndrome Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 脆弱X症候群遺伝子検査の世界市場規模・現状・予測2021年-2027年 Fragile X Syndrome Gene Test, designed to detect the Fragile X Syndrome gene Market Analysis and Insights: Global Fragile X Syndrome Genetic Testing Market The global Fragile X Syndrome Genetic Testing market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Fragile X Syndrome Genetic Testing market to help players in achieving a strong market position. Buyers of the report can access verified...
  • 脆弱X症候群遺伝子検査の世界市場規模・現状・予測2021年-2027年 Fragile X Syndrome Gene Test, designed to detect the Fragile X Syndrome gene Market Analysis and Insights: Global Fragile X Syndrome Genetic Testing Market The global Fragile X Syndrome Genetic Testing market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Fragile X Syndrome Genetic Testing market to help players in achieving a strong market position. Buyers of the report can access verified...
  • 多発性嚢胞腎治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Polycystic Kidney Disease Treatment Market The global Polycystic Kidney Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Polycystic Kidney Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Polycystic Kidney Disease...
  • ドラベ症候群治療の世界市場規模・現状・予測2021年-2027年 Dravet syndrome is a rare, severe form of intractable epilepsy. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells. Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include clobazam (Onfi, Frisium) and valproic acid (Depakote, Depakene). Second line treatments include stiripentol (Diacomit), topiramate (Topamax), and the ketogenic diet. Market Analysis and Insights: Global Dravet Syndrome Treatment Market The global Dravet Syndrome Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019,...
  • 多嚢胞性卵巣症候群治療の世界市場規模・現状・予測2021年-2027年 Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velvety skin. Market Analysis and Insights: Global Polycystic Ovarian Syndrome Treatment Market The global Polycystic Ovarian Syndrome Treatment market size is projected to reach US$ 3786.5 million by 2026, from US$ 3106.6 million in 2019, at a CAGR of 2.8% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a...
  • 周期的発熱症候群の世界市場規模・現状・予測2021年-2027年 Periodic fever syndrome are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation. The syndromes are diverse, but tend to cause episodes of fever, joint pains, skin rashes, abdominal pains and may lead to chronic complications such as amyloidosis. Market Analysis and Insights: Global Periodic Fever Syndrome Market The global Periodic Fever Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities...
  • セロトニン症候群の世界市場規模・現状・予測2021年-2027年 Serotonin syndrome is a group of symptoms such as high body temperature, agitation, increased reflexes, tremor, sweating, dilated pupils, diarrhoea etc. due to use of serotonergic drugs. Serious complications such as seizures and extensive muscle breakdown may occur which may lead to death. US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global serotonin syndrome diagnosis and treatment. Europe is the second largest market due to large disposable income and...
  • 吸収不良症候群の世界市場規模・現状・予測2021年-2027年 Malabsorption syndrome refers to a number of disorders in which the small intestine can’t absorb enough of certain nutrients and fluids. These nutrients can be macronutrients (proteins, carbohydrates, and fats), micronutrients (vitamins and minerals), or both. Treatment of Malabsorption is directed largely towards management of underlying cause. Replacement of nutrients, electrolytes and fluid may be necessary. In severe deficiency, hospital admission may be required for nutritional support and detailed advice from dietitians. Use of enteral nutrition by naso-gastric or other feeding tubes may be able to provide sufficient nutritional supplementation. Pancreatic enzymes are supplemented orally in pancreatic insufficiency. Dietary modification...
  • ロンバーグ病の世界市場規模・現状・予測2021年-2027年 Parry–Romberg syndrome, also known as progressive hemifacial atrophy, is a rare disease characterized by progressive shrinkage and degeneration of the tissues beneath the skin, usually on only one side of the face (hemifacial atrophy) but occasionally extending to other parts of the body. An autoimmune mechanism is suspected, and the syndrome may be a variant of localized scleroderma, but the precise cause and pathogenesis of this acquired disorder remains unknown. Medical management may involve immunosuppressive drugs such as methotrexate, corticosteroids, cyclophosphamide, and azathioprine. No randomized controlled trials have yet been conducted to evaluate such treatments, so the benefits have not...
  • 腫瘍崩壊症候群の世界市場規模・現状・予測2021年-2027年 Tumor lysis syndrome is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer, where large amounts of tumor cells are killed off (lysed) at the same time by the treatment, releasing their contents into the bloodstream. Market Analysis and Insights: Global Tumor Lysis Syndrome Market The global Tumor Lysis Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the...
  • チャーグストラウス症候群の世界市場規模・現状・予測2021年-2027年 Churg Strauss syndrome is a disorder that causes inflammation in blood vessels. This restricts the blood flow to vital organs and tissues. Sometimes it leads to permanent damage of tissues. This condition is also known as eosinophilic granulomatosis with polyangiitis. Asthma is the most common sign of churg Strauss syndrome. It also affects nose, sinuses, lung, heart, and nerves. Factors such as growing occurrences of churg Strauss syndrome and other allergic reactions and asthma, rising geriatric population, and growing incidences of churg Strauss syndrome in children are expected to drive the growth of the market during the assessment period. Market...
  • インピンジメント症候群の世界市場規模・現状・予測2021年-2027年 Impingement syndrome or subacromial impingement occurs when the tendons of the rotator cuff muscles become impinged and inflamed as they pass through the subacromial space. There are two major types of this disease, structural impingement and functional impingement. Different types of diagnosis methods like bone spurs, rotator cuff injury, labral injury, shoulder instability, biceps tendinopathy and scapula dysfunction can be used to diagnose this disorder. Increasing prevalence of orthopedic diseases, rising geriatric population and changing lifestyle have boosted the growth of the market. According to International Osteoporosis Foundation, worldwide osteoporosis causes more than 8.9 million fractures annually. Market Analysis and...
  • カルチノイド症候群管理の世界市場規模・現状・予測2021年-2027年 Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ. Market Analysis and Insights: Global Carcinoid Syndrome Management Market The global Carcinoid Syndrome Management market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a...
  • 多嚢胞性卵巣症候群（PCOS）治療の世界市場規模・現状・予測2021年-2027年 Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. Women with PCOS may have infrequent or prolonged menstrual periods or excess male hormone (androgen) levels. The ovaries may develop numerous small collections of fluid (follicles) and fail to regularly release eggs. Market Analysis and Insights: Global Polycystic Ovarian Syndrome (PCOS) Treatment Market The global Polycystic Ovarian Syndrome (PCOS) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes...
  • ドラベ症候群治療の世界市場規模・現状・予測2021年-2027年 Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Dravet Syndrome Thereapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Dravet Syndrome Thereapeutics market in terms...